Kala Bio (LTS:0JQ2) Loans Receivable: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0JQ2 Kala Bio Inc LTS:0JQ2
29 GF Score
Price $0.83
GF Value $1.98
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Kala Bio Loans Receivable?

Kala Bio LTS:0JQ2 -2.24% 29 Loans Receivable is $0.00 Mil as of Jun. 2026. GuruFocus rates LTS:0JQ2 with a GF Score™ of 29/100 and a GF Value™ of $1.98 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Kala Bio's Loans Receivable for the quarter that ended in Jun. 2026 was $0.00 Mil.

Kala Bio Loans Receivable Historical Data

* Premium members only.

The historical data trend for Kala Bio's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kala Bio Loans Receivable Chart

Kala Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kala Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0JQ2
29GF Score
Kala Bio Inc LTS:0JQ2
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kala Bio Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Kala Bio (LTS:0JQ2) has a Loans Receivable of $0.00 Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Kala Bio and its competitors.
Is Kala Bio's Loans Receivable too high?
Kala Bio's current Loans Receivable is $0.00 Mil. Overall, Kala Bio has a GF Score™ of 29/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kala Bio's Loans Receivable compare to GDTC and GTBP?
Kala Bio's Loans Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Kala Bio and its competitors. Kala Bio's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kala Bio stock overvalued right now?
Based on GuruFocus' analysis, Kala Bio (LTS:0JQ2) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.98, compared to a current price of $0.83 — trading 58.3% below its estimated fair value. The current Loans Receivable is $0.00 Mil. Kala Bio's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Kala Bio (LTS:0JQ2), the current Loans Receivable is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kala Bio (LTS:0JQ2) Overvalued in 2026?

Based on GuruFocus' analysis, Kala Bio stock appears to be undervalued. The current stock price of $0.83 is trading 58.3% below its estimated GF Value™ of $1.98. GuruFocus considers Kala Bio to be Significantly Undervalued.

Key valuation signals for LTS:0JQ2:

  • Loans Receivable: $0.00 Mil
  • GF Value™: $1.98 vs. price of $0.83 (58.3% below fair value)
  • GF Score™: 29/100 with 1 warning sign

No single metric tells the full story. See the LTS:0JQ2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kala Bio Business Description

Other Exchanges KALA:USA27F:Germany
Address 1167 Massachusetts Avenue, Arlington, MA, USA, 02476
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
29GF Score

Get the complete analysis for LTS:0JQ2

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.83
Price
$1.98
GF Value